EMA to review Selincro

EMA accepted for review an MAA from H. Lundbeck A/S (CSE:LUN) for Selincro nalmefene to treat alcohol dependence. Lundbeck has rights to the opioid receptor antagonist from Biotie Therapies Corp. (HSE...